恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响*

doi:10.3969/j.issn.1672-5069.2018.06.010

Abstract

Abstract: Objective To investigate the impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B （CHB） and nonalcoholic fatty liver disease （NAFLD）. Methods A total of 25 patients with histological-proved chronic hepatitis B（CHB） were enrolled in this prospective study. The patients were treated with entecavir for 96 weeks. The hydrogen proton spectroscopy（¹H-MRS） was performed and the life style was investigated by a questionnaire in all patients. Results 16 patients（64.0%） with CHB were found having liver steatosis≥F1 by liver biopsies. 21 patients （84.0%） obtained complete viralogic response at the end of 96 weeks;serum HBsAg and HBV DNA levels at baseline and at the end of observation were significantly different（P<0.05）,while there were no significant differences as respect to serum bilirubin,ALT,body mass index,waist-hip ratio and low-density lipoprotein cholesterol （P>0.05）;at the end of 96 weeks,8 were found having liver steatosis deteriorated,13 unchanged and 4 improved by the lipid-water ratio（LWR） of ¹H-MRS out of 16 patients with NAFLD and the waist-hip ratio decreased in those with improved steatosis（P<0.05）;the analysis of life habit showed that the staple food was the independent factor which influenced the outcome of hepatic steatosis （P<0.05）. Conclusion Entecavir treatment could not improve hepatic steatosis in patients with CHB and NAFLD,and the decreased waist-to-hip ratio might be associated the improvement of liver steatosis in those patients.

Key words: Hepatitis B, Nonalcoholic fatty liver disease, Entecavir, Magnetic resonance spectroscopy, Therapy

Huang Jiaofeng, Lin Su, Wang Mingfang, et al.. Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 863-867.

References

[1] Peng D,Han Y,Ding H,et al.Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol,2008,23(7 Pt 1):1082-1088.
[2] 王明芳,林苏,吴银莲, 等. 慢性乙型肝炎患者肝脂肪变性与血清、肝组织病毒因素的关系. 中华传染病杂志,2016,34(3): 141-145.
[3] Kim K,Kim KH,Kim HH,et al.Hepatitis B virus X protein induces lipogenic transcriptio nfactor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem J,2008,416(2):219-230.
[4] Joo EJ,Chang Y,Yeom JS,et al.Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease:A cohort study. Hepatology,2017,65(3):828-835.
[5] Hamilton G,Yokoo T,Bydder M, et al.In vivo characterization of the liver fat H MR spectrum. NMR Biomed,2011,24(7):784-790.
[6] Stern C,Castera L.Non-invasive diagnosis of hepatic steatosis. Hepatol Int,2017,11(1):70-78.
[7] AlShaalan R,Aljiffry M,Al-Busafi S,et al. Nonalcoholic fatty liver disease:Noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol,2015,21(2):64-70.
[8] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89.
[9] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志,2007,10(1):1-3.
[10] Xiao G,Zhu S,Xiao X,et al.Comparison of laboratory tests,ultrasound,or MRE to detect fibrosis in patients with non-alcoholic fatty liver disease:A meta-analysis. Hepatology,2017,52:1-45.
[11] Di Martino M,Pacifico L,Bezzi M,et al.Comparison of magnetic resonance spectroscopy,proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents. World J Gastroenterol,2016,22(39):8812-8819.
[12] Chan R,Wong VW,Chu WC,et al.Diet-quality scores and prevalence of nonalcoholic fatty liver disease:A population study using proton-magnetic resonance spectroscopy. PLoS One,2015,10(9): 0139310.
[13] 曹代荣,熊美连,邢振,等. 磁共振、CT定量分析肝脏脂肪变准确性的对比研究. 临床放射学杂志,2012,31(11):1578-1582.
[14] Machado MV,Oliveira AG,Cortez-Pinto H,et al.Hepatic steatosis in hepatitis B virus infected patients:meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol,2011,26(9):1361-1367.
[15] Jarcuska P,Drazilova S,Fedacko J,et al.Association between hepatitis B and metabolic syndrome:Current state of the art. World J Gastroenterol,2016,22(1):155-164.
[16] Wah-Kheong C,Khean-Lee G.Epidemiology of a fast emerging disease in the Asia-Pacific region:non-alcoholic fatty liver disease. Hepatol Int,2013,7(1):65-71.
[17] Jin X,Chen YP,Yang YD,et al.Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One,2012,7(3):e34198.
[18] Gong L,Liu J,Wang J,et al.Hepatic steatosis as a predictive factor of antiviral effect of pegylated interferon therapy in patients with hepatitis B. Transplant Proc,2015,47(10):2886-2891.
[19] Cindoruk M,Karakan T,Unal S,et al.Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol,2007,41(5):513-517.
[20] Zhu LY,Wang YG,Wei LQ,et al.The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease. Drug Des Devel Ther,2016,10:2739-2744.
[21] 蒋瓅,陈雪婉,郑瑞丹,等. 腰臀比为非酒精性单纯性脂肪肝最有效的预测指标. 中华肝脏病杂志,2010,18(11):859-861.

Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[4]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[5]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[6]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[7]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[8]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[9]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[10]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[11]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[12]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[13]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[14]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[15]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.